One pot preparation of muti-mode nanoplatform to combat ovarian cancer

Biomed Pharmacother. 2023 Sep:165:115172. doi: 10.1016/j.biopha.2023.115172. Epub 2023 Jul 18.

Abstract

Ovarian cancer is one of the most common gynecological cancers with high mortality rate. The battle against ovarian cancer usually impaired by the evolved multidrug resistance (MDR) phenotype as well as metastasis in cancers, which urgently call for the development of multi-mode strategies to overcome the MDR and reduce metastasis. Considering the good benefits of ferroptosis and photothermal therapy (PTT) in cancer management, we herein proposed a facile way to construct nanoparticle platform (Fe-Dox/PVP) composed of ferric chloride, doxorubicin (Dox) and polyvinyl pyrrolidone (PVP) for the multi-mode therapy of ovarian cancer using chemotherapy, ferroptosis and mild hypothermia PTT. Our results demonstrated that Fe-Dox/PVP with mild hypothermia was shown to have improved endosomal escape/drug delivery, enhanced ferroptosis induction and good tumor targeting effects. Most importantly, the integration of all three effects into one platform provided increased anti-metastasis effect and promising in vitro/in vivo anticancer performance with high biocompatibility. In this study, we offer a facile and robust way to prepare a multi-mode nanoplatform to combat ovarian cancer, which can be further extended for the management of many other cancers.

Keywords: Multidrug resistance; Muti-mode cancer therapy; Ovarian cancer; Photothermal therapy.

MeSH terms

  • Cell Line, Tumor
  • Doxorubicin / pharmacology
  • Drug Delivery Systems / methods
  • Female
  • Humans
  • Hypothermia*
  • Nanoparticles*
  • Ovarian Neoplasms* / drug therapy
  • Phototherapy / methods

Substances

  • Doxorubicin